Literature DB >> 20484427

PET assessment of myocardial perfusion reserve inversely correlates with intravascular ultrasound findings in angiographically normal cardiac transplant recipients.

Yen-Wen Wu1, Ying-Hsien Chen, Shoei-Shen Wang, Hsiang-Yiang Jui, Ruoh-Fang Yen, Kai-Yuan Tzen, Ming-Fong Chen, Chii-Ming Lee.   

Abstract

UNLABELLED: Cardiac allograft vasculopathy (CAV) is the major determinant of long-term survival after heart transplantation. We aimed to evaluate the efficacy of PET as a noninvasive way to assess the early stages of CAV.
METHODS: Twenty-seven consecutive patients (20 men and 7 women; mean age +/- SD, 46 +/- 12 y) who had normal results on coronary angiography and normal left ventricular systolic function (ejection fraction >or= 60%) were enrolled at 2.5 +/- 2.1 y after transplantation. Myocardial blood flow (MBF) was assessed using dynamic (13)N-ammonia PET at rest and during adenosine-induced hyperemia, and myocardial perfusion reserve (MPR) was calculated as the ratio of hyperemic MBF to resting MBF. Regional (13)N-ammonia PET was assessed using a 5-point scoring system. The intravascular ultrasound (IVUS) measurements for the extent of intimal hyperplasia, including plaque volume index (calculated as [total plaque volume/total vessel volume] x 100%) and maximum area of stenosis, were compared with MPR by linear regression analysis.
RESULTS: In 27 angiographically normal cardiac transplant recipients, MBF at rest and during adenosine stress and MPR of the left anterior descending artery distribution correlated strongly with the other 2 coronary artery distribution territories (r >or= 0.97, P < 0.0001). Summed stress score and summed difference score showed a moderate inverse correlation with MPR (r = -0.41 and -0.49, respectively; P < 0.05) but not with IVUS measurements. MPR correlated inversely with plaque volume index (r = -0.40, P < 0.05) but not with maximal luminal stenosis as assessed by IVUS. In addition, MPR and IVUS measurements gradually inversely changed after heart transplantation (all P < 0.05).
CONCLUSION: This study confirms that CAV is a progressive process, diffusely involving the epicardial and microvascular coronary system. Plaque burden as determined by IVUS agrees well with MPR as assessed by PET in recipients with normal coronary angiography results. This finding suggests that dynamic (13)N-ammonia PET is clinically feasible for the early detection of CAV and can be used as a reliable marker of disease progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484427     DOI: 10.2967/jnumed.109.073833

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

Review 1.  Transplant allograft vasculopathy: Role of multimodality imaging in surveillance and diagnosis.

Authors:  Gregory A Payne; Fadi G Hage; Deepak Acharya
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

2.  Semi-quantitative myocardial perfusion MRI in heart transplant recipients at rest: repeatability in healthy controls and assessment of cardiac allograft vasculopathy.

Authors:  Travis B DeSa; Muhannad A Abbasi; Julie A Blaisdell; Kai Lin; Jeremy D Collins; James C Carr; Michael Markl
Journal:  Clin Imaging       Date:  2019-12-19       Impact factor: 1.605

3.  Carotid and brachial artery intima-media thickness is related to coronary atherosclerotic burden and may also represent high cardiovascular risk in patients with normal coronary angiograms.

Authors:  Ömer Şatiroğlu; Sinan Altan Kocaman; Nermin Bayar; Turan Erdoğan; Yüksel Çiçek; Filiz Taşçı; Engin Bozkurt
Journal:  J Med Ultrason (2001)       Date:  2011-08-11       Impact factor: 1.314

Review 4.  Quantification of PET Myocardial Blood Flow.

Authors:  Matthieu Pelletier-Galarneau; Patrick Martineau; Georges El Fakhri
Journal:  Curr Cardiol Rep       Date:  2019-02-28       Impact factor: 2.931

5.  Regadenoson-induced hyperemia for absolute myocardial blood flow quantitation by 13N-ammonia PET and detection of cardiac allograft vasculopathy.

Authors:  René R Sevag Packard; Jamshid Maddahi
Journal:  J Nucl Cardiol       Date:  2017-01-30       Impact factor: 5.952

6.  Should positron emission tomography be the standard of care for non-invasive surveillance following cardiac transplantation?

Authors:  Robert J H Miller; Jon A Kobashigawa; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2018-11-12       Impact factor: 5.952

7.  Myocardial perfusion imaging for cardiac allograft vasculopathy assessment: Evidence grows, but questions remain.

Authors:  Deepak Acharya; Indranee Rajapreyar
Journal:  J Nucl Cardiol       Date:  2017-11-07       Impact factor: 5.952

8.  Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC.

Authors:  Venkatesh L Murthy; Timothy M Bateman; Rob S Beanlands; Daniel S Berman; Salvador Borges-Neto; Panithaya Chareonthaitawee; Manuel D Cerqueira; Robert A deKemp; E Gordon DePuey; Vasken Dilsizian; Sharmila Dorbala; Edward P Ficaro; Ernest V Garcia; Henry Gewirtz; Gary V Heller; Howard C Lewin; Saurabh Malhotra; April Mann; Terrence D Ruddy; Thomas H Schindler; Ronald G Schwartz; Piotr J Slomka; Prem Soman; Marcelo F Di Carli; Andrew Einstein; Raymond Russell; James R Corbett
Journal:  J Nucl Cardiol       Date:  2018-02       Impact factor: 5.952

9.  Safety of regadenoson positron emission tomography stress testing in orthotopic heart transplant patients.

Authors:  John J Lazarus; Ashraf Saleh; Michael Ghannam; Keith Aaronson; Monica Colvin; Frank Pagani; Todd Koelling; James R Corbett; Richard L Weinberg; Venkatesh L Murthy; Matthew C Konerman
Journal:  J Nucl Cardiol       Date:  2018-11-27       Impact factor: 5.952

10.  Coronary collaterals predict improved survival and allograft function in patients with coronary allograft vasculopathy.

Authors:  Kory J Lavine; Marc Sintek; Eric Novak; Gregory Ewald; Edward Geltman; Susan Joseph; John Pfeifer; Douglas L Mann
Journal:  Circ Heart Fail       Date:  2013-05-24       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.